東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

The prostate cancer dilemma = select...

Stone, Nelson N.

Linked to FindBook

Google Book

Amazon

博客來

The prostate cancer dilemma = selecting patients for active surveillance, focal ablation and definitive therapy /

Record Type:	Electronic resources : Monograph/item
Title/Author:	The prostate cancer dilemma/ edited by Nelson N. Stone, E. David Crawford.
Reminder of title:	selecting patients for active surveillance, focal ablation and definitive therapy /
other author:	Stone, Nelson N.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	xiv, 206 p. :ill., digital ;24 cm.
[NT 15003449]:	Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.
Contained By:	Springer eBooks
Subject:	Prostate - Cancer. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-21485-6
ISBN:	9783319214856$q(electronic bk.)

The prostate cancer dilemma = selecting patients for active surveillance, focal ablation and definitive therapy /
The prostate cancer dilemmaselecting patients for active surveillance, focal ablation and definitive therapy /[electronic resource] :edited by Nelson N. Stone, E. David Crawford. - Cham :Springer International Publishing :2016. - xiv, 206 p. :ill., digital ;24 cm.

Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.

This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.

ISBN: 9783319214856$q(electronic bk.)

Standard No.: 10.1007/978-3-319-21485-6doiSubjects--Topical Terms:

800639
Prostate
--Cancer.

LC Class. No.: RC280.P7

Dewey Class. No.: 616.99463

The prostate cancer dilemma = selecting patients for active surveillance, focal ablation and definitive therapy /
LDR:03313nmm a2200313 a 4500 001 2029356
003 DE-He213
005 20160727103415.0
006 m d
007 cr nn 008maaau
008 160908s2016 gw s 0 eng d
020 $a 9783319214856$q(electronic bk.)
020 $a 9783319214849$q(paper)
024 7 $a 10.1007/978-3-319-21485-6 $2 doi
035 $a 978-3-319-21485-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.P7
072 7 $a MJS $2 bicssc
072 7 $a MED088000 $2 bisacsh
082 0 4 $a 616.99463 $2 23
090 $a RC280.P7 $b P966 2016
245 0 4 $a The prostate cancer dilemma $h [electronic resource] : $b selecting patients for active surveillance, focal ablation and definitive therapy / $c edited by Nelson N. Stone, E. David Crawford.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a xiv, 206 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part One: Diagnosis -- History of PSA, from Detection to Over Diagnosis -- Pathology of Prostate Cancer: What has Changed in the Last 30 years?- Clinical Risk Prediction Tools for Prostate Cancer: TMN to CAPRA-Should Risk be Re-defined?- TRUS Biopsy: Is There Still a Role?- Transperineal Biopsy Technique -- 3D Biopsy: A New Method to Diagnose Prostate Cancer -- Elastography: Can it Improve Prostate Biopsy Results?- Multi parametric MRI of the Prostate as a Tool for Prostate Cancer Detection -- Genomic Markers -- Part Two: Treatment -- Current Status of Clinical Trials in Active Surveillance -- Focused targeted Therapy in Prostate Cancer -- Technologies and Methods in Primary Ablation with Focal Therapy -- Multi parametric MRI (mpMRI)-Guided Focal Therapy -- Conclusions.
520 $a This comprehensive text provides a complete description of the newest technologies to diagnose and manage the most common prostate cancer diagnosed today: low risk disease. The book reviews new data about genetic markers, transperineal mapping biopsy and mpMRI, how to apply each of these technologies in patients with elevated PSA, when a prior prostate biopsy performed by the standard TRUS method is negative, and, in cases where low risk disease is already diagnosed, how to differentiate those men who might harbor more aggressive disease from those who do not. Over 75% of newly diagnosed prostate cancer meets the criteria for low risk disease which has created a dilemma for both patients and clinicians because of the inaccuracy of the standard TRUS biopsy method. Active surveillance programs have been initiated and are reviewed. How the new technologies impact surveillance programs are addressed. Clinical stage designation is updated and a new intra-prostatic staging system is discussed. Prostate biopsy techniques utilizing transrectal ultrasound, transperineal mapping, elastography and mpMRI are compared. Finally, utilization of these new technologies in the application of focal therapy is reviewed. The Prostate Cancer Dilemma will serve as a valuable resource for clinicians, surgeons and researchers with an interest in early prostate cancer. Chapters are written by experts in their fields and include the most up-to-date scientific and clinical information as well as links to procedural video content.
650 0 $a Prostate $x Cancer. $3 800639
650 0 $a Prostate $x Cancer $x Diagnosis. $3 852652
650 0 $a Prostate $x Cancer $x Treatment. $3 852653
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Urology. $3 636586
650 2 4 $a Oncology. $3 751006
650 2 4 $a Pathology. $3 643180
700 1 $a Stone, Nelson N. $3 2180305
700 1 $a Crawford, E. David. $3 2180306
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-21485-6
950 $a Medicine (Springer-11650)